<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2025-15-2-102-116</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-1956</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Клапанная болезнь сердца при антифосфолипидном синдроме (обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>Valvular Heart Disease In Antiphospholipid Syndrome (Review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3611-1186</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Игнатенко</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ignatenko</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Игнатенко Григорий Анатольевич — д.м.н., ректор ФГБОУ ВО ДонГМУ МЗ РФ, заведующий кафедрой пропедевтики внутренних болезней с лабораторией адаптационной медицины</p><p>Донецк</p></bio><bio xml:lang="en"><p>Grigory A. Ignatenko — MD, Rector of the Federal State Budgetary Educational Institution of Higher Education Donetsk State Medical University of the Ministry of Health of the Russian Federation, Head of the Department of Propaedeutics of Internal Diseases with the Laboratory of Adaptive Medicine</p><p>Donetsk</p></bio><email xlink:type="simple">gai-1959@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3984-8482</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарадин</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Taradin</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарадин Геннадий Геннадьевич — к.м.н., заведующий кафедрой терапии им. проф. А.И. Дядыка ФНМФО ФГБОУ ВО ДонГМУ МЗ РФ</p><p>Донецк</p></bio><bio xml:lang="en"><p>Gennady G. Taradin — PhD, Head of the Department of Therapy named after prof. A.I. Dyadyk, FNMFO FSBEI HE DonSMU MH RF</p><p>Donetsk</p></bio><email xlink:type="simple">taradin@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-4560-2632</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кононенко</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kononenko</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кононенко Людмила Викторовна — ассистент кафедры терапии им. проф. А.И. Дядыка ФНМФО ФГБОУ ВО ДонГМУ МЗ РФ</p><p>Донецк</p></bio><bio xml:lang="en"><p>Lyudmila V. Kononenko — assistant of the Department of Therapy named after prof. A.I. Dyadyk FNMFO FGBOU VO DonSMU MH RF</p><p>Donetsk</p></bio><email xlink:type="simple">liudmilavikkononenko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2694-6614</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ракитская</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakitskaya</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ракитская Ирина Валериевна — к.м.н., доцент кафедры терапии им. проф. А.И. Дядыка ФНМФО ФГБОУ ВО ДонГМУ МЗ РФ</p><p>Донецк</p></bio><bio xml:lang="en"><p>Irina V. Rakitskaya — PhD, Associate Professor of the Department of Therapy named after prof. A.I. Dyadyk FNMFO FSBEI HE DonSMU MH RF</p><p>Donetsk</p></bio><email xlink:type="simple">rakytskaya@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-8279-0469</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кагитина</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kagitina</surname><given-names>Y. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кагитина Юлия Сергеевна — врач-терапевт консультативной поликлиники № 1 ГБУ ДНР «Республиканская клиническая больница имени М.И. Калинина» МЗ РФ</p><p>Донецк</p></bio><bio xml:lang="en"><p>Yulia S. Kagitina — physician-therapist of the consultative polyclinic No. 1 of th e State Budgetary Institution of the DPR “Republican Clinical Hospital named after M.I. Kalinin” of the Ministry of Health of the Russian Federation</p><p>Donetsk</p></bio><email xlink:type="simple">ykagitina@inbox.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6031-2124</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прендергаст</surname><given-names>Б. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Prendergast</surname><given-names>B. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Прендергаст Бернард Дэвид — д.м.н., заведующий кардиологическим отделом Кливленд Клиники Лондона</p><p>Лондон</p></bio><bio xml:lang="en"><p>Bernard D. Prendergast — MD, Head of Cardiology, Cleveland Clinic London</p><p>London</p></bio><email xlink:type="simple">bernard.prendergast@gstt.nhs.uk</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования «Донецкий государственный медицинский университет имени М. Горького» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Federal State-Funded Educational Institution of Higher Education Donetsk State Medical University named after M. Gorky, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение Донецкой Народной Республики «Республиканская клиническая больница имени М.И. Калинина» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Budgetary Institution of the Donetsk People’s Republic «M.I. Kalinin’s Republican Clinical Hospital» of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кливленд Клиника Лондона; Госпиталь Томаса</institution><country>Великобритания</country></aff><aff xml:lang="en"><institution>Cleveland Clinic London; Thomas’ Hospital, Westminster Bridge Road</institution><country>United Kingdom</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>03</month><year>2025</year></pub-date><volume>15</volume><issue>2</issue><fpage>102</fpage><lpage>116</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Игнатенко Г.А., Тарадин Г.Г., Кононенко Л.В., Ракитская И.В., Кагитина Ю.С., Прендергаст Б.Д., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Игнатенко Г.А., Тарадин Г.Г., Кононенко Л.В., Ракитская И.В., Кагитина Ю.С., Прендергаст Б.Д.</copyright-holder><copyright-holder xml:lang="en">Ignatenko G.A., Taradin G.G., Kononenko L.V., Rakitskaya I.V., Kagitina Y.S., Prendergast B.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/1956">https://www.medarhive.ru/jour/article/view/1956</self-uri><abstract><p>Обзор посвящен особенностям клапанной болезни сердца (КБС) при антифосфолипидном синдроме (АФС). Кроме эпидемиологических данных и классификационных критериев АФС, приводятся сведения о распространенности, патогенетических механизмах, патоморфологических особенностях КБС, которая характеризуется веррукозным эндокардитом (или эндокардитом Либмана-Сакса), утолщением створок и дисфункцией клапанов. Основные патогенетические события КБС обусловлены воздействием антифосфолипидных антител, локальной агрегацией тромбоцитов, миграцией воспалительных клеток и отложением иммунных комплексов. Течение КБС при АФС нередко осложняется тромбоэмболическими осложнениями, включая эмболизацию артерий головного мозга и коронарных артерий. Диагностика КБС при АФС основывается на результатах эхокардиографии (ЭхоКГ), что позволяет выявить утолщение створок, веррукозные образования и оценить функцию клапанного аппарата. Использование чреспищеводной ЭхоКГ позволяет уточнить особенности клапанного поражения при неубедительных результатах трансторакальной ЭхоКГ. Обсуждаются вопросы ведения больных с АФС, имеющих КБС, с оценкой результатов применения антитромбоцитарной, антикоагулянтной, иммуносупрессивной терапии и хирургической коррекции выраженной клапанной патологии. Выполнение кардиохирургических вмешательств ассоциируется с повышенным риском развития послеоперационных осложнений, обусловленных кровотечениями или тромбозом, а также смертности.</p></abstract><trans-abstract xml:lang="en"><p>The review concerns special aspects of valvular heart disease (VHD) in antiphospholipid syndrome (APS). In addition to epidemiological data and classification criteria for APS, information is provided on the prevalence, pathogenetic mechanisms, and pathomorphological features of VHD, which is characterized by verrucous endocarditis (or Libman-Sacks endocarditis), thickening of the leaflets and valve dysfunction. The main pathogenetic events of VHD are caused by the effects of antiphospholipid antibodies, local platelet aggregation, migration of inflammatory cells and deposition of immune complexes. The course of VHD in APS is often complicated by thromboembolic complications, including embolization of the cerebral arteries and coronary arteries. Diagnosis of VHD in APS is based primary on the results of echocardiography, which allows to identify leaflet thickening, verrucous vegetations and assess the function of the valve apparatus. The use of transesophageal echocardiography makes it possible to clarify the features of valvular lesions in case of inconclusive results of transthoracic echocardiography. The issues of management of patients with and VHD are discussed, with an assessment of the results of the use of antiplatelet, anticoagulant, immunosuppressive therapy and surgical correction of severe valvular pathology. Cardiac surgery is associated with an increased risk of postoperative complications due to bleeding or thrombosis, as well as mortality.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>антифосфолипидный синдром</kwd><kwd>клапанная болезнь сердца</kwd><kwd>эндокардит Либмана-Сакса</kwd><kwd>вальвулит</kwd><kwd>эхокардиография</kwd><kwd>лечение</kwd><kwd>тромбоэмболические осложнения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>антифосфолипидный синдром</kwd><kwd>клапанная болезнь сердца</kwd><kwd>эндокардит Либмана-Сакса</kwd><kwd>вальвулит</kwd><kwd>эхокардиография</kwd><kwd>лечение</kwd><kwd>тромбоэмболические осложнения</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, et al. The pathophysiology of the antiphospholipid syndrome: a perspective from the blood coagulation system. Clin Appl Thromb Hemost. 2022;28:10760296221088576. doi: 10.1177/10760296221088576</mixed-citation><mixed-citation xml:lang="en">Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, et al. The pathophysiology of the antiphospholipid syndrome: a perspective from the blood coagulation system. Clin Appl Thromb Hemost. 2022;28:10760296221088576. doi: 10.1177/10760296221088576</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. doi: 10.1136/ard-2023-224609</mixed-citation><mixed-citation xml:lang="en">Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. doi: 10.1136/ard-2023-224609</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao M, Zhang Y, Zhang S, et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 2020;72(12):1998-2004. doi: 10.1002/art.41425</mixed-citation><mixed-citation xml:lang="en">Xiao M, Zhang Y, Zhang S, et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 2020;72(12):1998-2004. doi: 10.1002/art.41425</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, et al. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2022;23(12):85. doi: 10.1007/s11926-021-01038-2</mixed-citation><mixed-citation xml:lang="en">Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, et al. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2022;23(12):85. doi: 10.1007/s11926-021-01038-2</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yao WC, Leong KH, Chiu LT, et al. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Thromb J. 2022;20(1):50. doi: 10.1186/s12959-022-00409-8</mixed-citation><mixed-citation xml:lang="en">Yao WC, Leong KH, Chiu LT, et al. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Thromb J. 2022;20(1):50. doi: 10.1186/s12959-022-00409-8</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">APS Foundation of America, Inc. 14.11.2024 [Internet]. English. Available from: https://apsfa.org</mixed-citation><mixed-citation xml:lang="en">APS Foundation of America, Inc. 14.11.2024 [Internet]. English. Available from: https://apsfa.org</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Corban MT, Duarte-Garcia A, McBane RD, et al. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol. 2017;69(18):2317-2330. doi: 10.1016/j.jacc.2017.02.058</mixed-citation><mixed-citation xml:lang="en">Corban MT, Duarte-Garcia A, McBane RD, et al. Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J Am Coll Cardiol. 2017;69(18):2317-2330. doi: 10.1016/j.jacc.2017.02.058</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nevras V, Milaras N, Katsioulis C, et al. Acute coronary syndromes in antiphospholipid syndrome-above suspicion: a systematic review. Curr Probl Cardiol. 2023;48(3):101503. doi: 10.1016/j.cpcardiol.2022.101503.</mixed-citation><mixed-citation xml:lang="en">Nevras V, Milaras N, Katsioulis C, et al. Acute coronary syndromes in antiphospholipid syndrome-above suspicion: a systematic review. Curr Probl Cardiol. 2023;48(3):101503. doi: 10.1016/j.cpcardiol.2022.101503.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tufano A, Di Minno MND, Guida A, et al. Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies. Semin Thromb Hemost. 2019;45(5):468-477. doi: 10.1055/s-0039-1692702</mixed-citation><mixed-citation xml:lang="en">Tufano A, Di Minno MND, Guida A, et al. Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies. Semin Thromb Hemost. 2019;45(5):468-477. doi: 10.1055/s-0039-1692702</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M. Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):415-420. doi: 10.1182/hematology.2019000046</mixed-citation><mixed-citation xml:lang="en">Petri M. Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):415-420. doi: 10.1182/hematology.2019000046</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501. doi: 10.1002/acr.24520.</mixed-citation><mixed-citation xml:lang="en">Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501. doi: 10.1002/acr.24520.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. doi: 10.1056/NEJMra1705454</mixed-citation><mixed-citation xml:lang="en">Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021. doi: 10.1056/NEJMra1705454</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M. Antiphospholipid syndrome. Transl Res. 2020;225:70-81. doi: 10.1016/j.trsl.2020.04.006</mixed-citation><mixed-citation xml:lang="en">Petri M. Antiphospholipid syndrome. Transl Res. 2020;225:70-81. doi: 10.1016/j.trsl.2020.04.006</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x</mixed-citation><mixed-citation xml:lang="en">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobs L, Wauters N, Lablad Y, et al. Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Antibodies (Basel). 2024;13(1):21. doi: 10.3390/antib13010021</mixed-citation><mixed-citation xml:lang="en">Jacobs L, Wauters N, Lablad Y, et al. Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Antibodies (Basel). 2024;13(1):21. doi: 10.3390/antib13010021</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kolitz T, Shiber S, Sharabi I, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019;10:941. doi: 10.3389/fimmu.2019.00941</mixed-citation><mixed-citation xml:lang="en">Kolitz T, Shiber S, Sharabi I, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019;10:941. doi: 10.3389/fimmu.2019.00941</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo BW, Lee SW, Song JJ, et al. Clinical characteristics and longterm outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. Lupus. 2020;29(9):1115-1120. doi: 10.1177/0961203320930097</mixed-citation><mixed-citation xml:lang="en">Yoo BW, Lee SW, Song JJ, et al. Clinical characteristics and longterm outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. Lupus. 2020;29(9):1115-1120. doi: 10.1177/0961203320930097</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pons I, Louro J, Sitges M, et al. Heart valve involvement in patients with antiphospholipid syndrome: a long-term followup study of a single centre. J Clin Med. 2023;12(8):2996. doi: 10.3390/jcm12082996</mixed-citation><mixed-citation xml:lang="en">Pons I, Louro J, Sitges M, et al. Heart valve involvement in patients with antiphospholipid syndrome: a long-term followup study of a single centre. J Clin Med. 2023;12(8):2996. doi: 10.3390/jcm12082996</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zmaili MA, Alzubi JM, Kocyigit D, et al. A contemporary 20-year Cleveland Clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes. Am J Med. 2021;134(3):361-369. doi: 10.1016/j.amjmed.2020.06.047</mixed-citation><mixed-citation xml:lang="en">Zmaili MA, Alzubi JM, Kocyigit D, et al. A contemporary 20-year Cleveland Clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes. Am J Med. 2021;134(3):361-369. doi: 10.1016/j.amjmed.2020.06.047</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Venepally NR, Arsanjani R, Agasthi P, et al. A new insight into nonbacterial thrombotic endocarditis: a systematic review of cases. Anatol J Cardiol. 2022;26(10):743-749. doi: 10.5152/AnatolJCardiol.2022.1282</mixed-citation><mixed-citation xml:lang="en">Venepally NR, Arsanjani R, Agasthi P, et al. A new insight into nonbacterial thrombotic endocarditis: a systematic review of cases. Anatol J Cardiol. 2022;26(10):743-749. doi: 10.5152/AnatolJCardiol.2022.1282</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Бахарева ЮС, Максимов ВН, Чапаева НН. Генетические аспекты неинфекционного эндокардита у пациентов с антифосфолипидным синдромом. Медицина и образование в Сибири. 2022;6(2):51–61. DOI: 10.31549/2542-1174-2022-6-2-51-61.</mixed-citation><mixed-citation xml:lang="en">Bakhareva YuS, Maksimov VN, Chapaeva NN. Genetic aspects of non-infectious endocarditis in patients with antiphospholipid syndrome. Journal of Siberian Medical Sciences. 2022;6(2):51–61. doi: 10.31549/2542-1174-2022-6-2-51-61 [In Russian]</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Serrano R, Pons-Estel GJ, Espinosa G, et al. Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. Lupus. 2020;29(9):1050-1059. doi: 10.1177/0961203320933009</mixed-citation><mixed-citation xml:lang="en">Serrano R, Pons-Estel GJ, Espinosa G, et al. Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. Lupus. 2020;29(9):1050-1059. doi: 10.1177/0961203320933009</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S, Zhou Y, Wang C, et al. Impact of antiphospholipid antibodies on cardiac valve lesions in systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Med. 2024;24(1):147. doi: 10.1007/s10238-024-01406-z</mixed-citation><mixed-citation xml:lang="en">Chen S, Zhou Y, Wang C, et al. Impact of antiphospholipid antibodies on cardiac valve lesions in systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Med. 2024;24(1):147. doi: 10.1007/s10238-024-01406-z</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Koniari I, Siminelakis SN, Baikoussis NG, et al. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg. 2010;5:101. doi: 10.1186/1749-8090-5-101</mixed-citation><mixed-citation xml:lang="en">Koniari I, Siminelakis SN, Baikoussis NG, et al. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg. 2010;5:101. doi: 10.1186/1749-8090-5-101</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Mavrogeni SI, Sfikakis PP, Kitas GD, et al. Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. Semin Arthritis Rheum. 2016;45(5):611-616. doi: 10.1016/j.semarthrit.2015.09.005</mixed-citation><mixed-citation xml:lang="en">Mavrogeni SI, Sfikakis PP, Kitas GD, et al. Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. Semin Arthritis Rheum. 2016;45(5):611-616. doi: 10.1016/j.semarthrit.2015.09.005</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Zuily S, Huttin O, Mohamed S, et al. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep. 2013;15(4):320. doi: 10.1007/s11926-013-0320-8</mixed-citation><mixed-citation xml:lang="en">Zuily S, Huttin O, Mohamed S, et al. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep. 2013;15(4):320. doi: 10.1007/s11926-013-0320-8</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Nagy N, Bói B, Papp G, et al. Antiphospholipid antibodies are major risk factors for non-thrombotic cardiac complications in systemic lupus erythematosus. Biomedicines. 2024;12(3):530. doi: 10.3390/biomedicines12030530</mixed-citation><mixed-citation xml:lang="en">Nagy N, Bói B, Papp G, et al. Antiphospholipid antibodies are major risk factors for non-thrombotic cardiac complications in systemic lupus erythematosus. Biomedicines. 2024;12(3):530. doi: 10.3390/biomedicines12030530</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124(2):215-224. doi: 10.1161/CIRCULATIONAHA.111.028522</mixed-citation><mixed-citation xml:lang="en">Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124(2):215-224. doi: 10.1161/CIRCULATIONAHA.111.028522</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Denas G, Jose SP, Bracco A, et al. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015;14(3):214-22. doi: 10.1016/j.autrev.2014.11.003</mixed-citation><mixed-citation xml:lang="en">Denas G, Jose SP, Bracco A, et al. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015;14(3):214-22. doi: 10.1016/j.autrev.2014.11.003</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Generali E, Folci M, Selmi C, et al. Immune-mediated heart disease. Adv Exp Med Biol. 2017;1003:145-171. doi: 10.1007/978-3-319-57613-8_8</mixed-citation><mixed-citation xml:lang="en">Generali E, Folci M, Selmi C, et al. Immune-mediated heart disease. Adv Exp Med Biol. 2017;1003:145-171. doi: 10.1007/978-3-319-57613-8_8</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci. 2018;355(3):293-298. doi: 10.1016/j.amjms.2017.07.007</mixed-citation><mixed-citation xml:lang="en">Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci. 2018;355(3):293-298. doi: 10.1016/j.amjms.2017.07.007</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Le Ho Y, Ahmad Zaidi NA, Salleh A, et al. Aortic valve surgery for aortic regurgitation caused by Libman-Sacks endocarditis in a patient with primary antiphospholipid syndrome: a case report. J Cardiothorac Surg. 2021;16(1):92. doi: 10.1186/s13019-021-01458-2</mixed-citation><mixed-citation xml:lang="en">Le Ho Y, Ahmad Zaidi NA, Salleh A, et al. Aortic valve surgery for aortic regurgitation caused by Libman-Sacks endocarditis in a patient with primary antiphospholipid syndrome: a case report. J Cardiothorac Surg. 2021;16(1):92. doi: 10.1186/s13019-021-01458-2</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Bernardi M, Spadafora L, Andaloro S, et al. Management of cardiovascular complications in antiphospholipid syndrome: a narrative review with a focus on older adults. J Clin Med. 2024;13(11):3064. doi: 10.3390/jcm13113064</mixed-citation><mixed-citation xml:lang="en">Bernardi M, Spadafora L, Andaloro S, et al. Management of cardiovascular complications in antiphospholipid syndrome: a narrative review with a focus on older adults. J Clin Med. 2024;13(11):3064. doi: 10.3390/jcm13113064</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zuo Y, Navaz S, Liang W, et al. Prevalence of antiphospholipid antibodies and association with incident cardiovascular events. JAMA Netw Open. 2023;6(4):e236530. doi: 10.1001/jamanetworkopen.2023.6530</mixed-citation><mixed-citation xml:lang="en">Zuo Y, Navaz S, Liang W, et al. Prevalence of antiphospholipid antibodies and association with incident cardiovascular events. JAMA Netw Open. 2023;6(4):e236530. doi: 10.1001/jamanetworkopen.2023.6530</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Djokovic A, Stojanovich L, Kontic M, et al. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J. 2014;16(3):162-167</mixed-citation><mixed-citation xml:lang="en">Djokovic A, Stojanovich L, Kontic M, et al. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J. 2014;16(3):162-167</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">García-Torres R, Amigo MC, de la Rosa A, et al. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus. 1996; 5(1):56-61. doi: 10.1177/096120339600500111</mixed-citation><mixed-citation xml:lang="en">García-Torres R, Amigo MC, de la Rosa A, et al. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus. 1996; 5(1):56-61. doi: 10.1177/096120339600500111</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996; 5(3):196-205. doi: 10.1177/096120339600500306</mixed-citation><mixed-citation xml:lang="en">Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996; 5(3):196-205. doi: 10.1177/096120339600500306</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Blank M, Shani A, Goldberg I, et al. Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004; 114(5-6):589-592. doi: 10.1016/j.thromres.2004.06.039</mixed-citation><mixed-citation xml:lang="en">Blank M, Shani A, Goldberg I, et al. Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004; 114(5-6):589-592. doi: 10.1016/j.thromres.2004.06.039</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Lecompte T, Wahl D, Perret-Guillaume C, et al. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92(5):714-5. doi: 10.3324/haematol.10577</mixed-citation><mixed-citation xml:lang="en">Lecompte T, Wahl D, Perret-Guillaume C, et al. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92(5):714-5. doi: 10.3324/haematol.10577</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Yordan-Lopez NM, Hernandez-Suarez DF, Marshall-Perez L, et al. Nonbacterial thrombotic endocarditis of the tricuspid valve in a male patient with antiphospholipid syndrome. Cureus. 2018;10(5):e2695. doi: 10.7759/cureus.2695</mixed-citation><mixed-citation xml:lang="en">Yordan-Lopez NM, Hernandez-Suarez DF, Marshall-Perez L, et al. Nonbacterial thrombotic endocarditis of the tricuspid valve in a male patient with antiphospholipid syndrome. Cureus. 2018;10(5):e2695. doi: 10.7759/cureus.2695</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Migliorini S, Santoro C, Scatteia A, et al. A rare case of tricuspid valve Libman-Sacks endocarditis in a pregnant woman with primary antiphospholipid syndrome. J Clin Med. 2022; 11(19):5875. doi: 10.3390/jcm11195875</mixed-citation><mixed-citation xml:lang="en">Migliorini S, Santoro C, Scatteia A, et al. A rare case of tricuspid valve Libman-Sacks endocarditis in a pregnant woman with primary antiphospholipid syndrome. J Clin Med. 2022; 11(19):5875. doi: 10.3390/jcm11195875</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria aps manifestations (i): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20(2):165-173. doi: 10.1177/0961203310395051</mixed-citation><mixed-citation xml:lang="en">Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria aps manifestations (i): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20(2):165-173. doi: 10.1177/0961203310395051</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Niznik S, Rapoport MJ, Avnery O, et al. Heart valve disease in primary antiphospholipid syndrome. Rheumatology (Oxford). 2024;63(5):1397-1402. doi: 10.1093/rheumatology/kead399</mixed-citation><mixed-citation xml:lang="en">Niznik S, Rapoport MJ, Avnery O, et al. Heart valve disease in primary antiphospholipid syndrome. Rheumatology (Oxford). 2024;63(5):1397-1402. doi: 10.1093/rheumatology/kead399</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Nagi T, Sahu N, Usmani N, et al. Unusual presentation of isolated nonbacterial thrombotic tricuspid valve endocarditis in systemic lupus erythematosus with secondary antiphospholipid syndrome: A Case Report. J Med Cases. 2022;13(7):330-334. doi: 10.14740/jmc3950</mixed-citation><mixed-citation xml:lang="en">Nagi T, Sahu N, Usmani N, et al. Unusual presentation of isolated nonbacterial thrombotic tricuspid valve endocarditis in systemic lupus erythematosus with secondary antiphospholipid syndrome: A Case Report. J Med Cases. 2022;13(7):330-334. doi: 10.14740/jmc3950</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010; 19(5):575-582. doi: 10.1177/0961203309353772.</mixed-citation><mixed-citation xml:lang="en">Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010; 19(5):575-582. doi: 10.1177/0961203309353772.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003; 12(11):805-812. doi: 10.1191/0961203303lu468oa</mixed-citation><mixed-citation xml:lang="en">Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003; 12(11):805-812. doi: 10.1191/0961203303lu468oa</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95(12):1441-1447. doi: 10.1016/j.amjcard.2005.02.010</mixed-citation><mixed-citation xml:lang="en">Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95(12):1441-1447. doi: 10.1016/j.amjcard.2005.02.010</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108(4):331-337. doi: 10.1159/000099104</mixed-citation><mixed-citation xml:lang="en">Roldan CA, Gelgand EA, Qualls CR, et al. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108(4):331-337. doi: 10.1159/000099104</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64(10):1490-3. doi: 10.1136/ard.2004.032813</mixed-citation><mixed-citation xml:lang="en">Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64(10):1490-3. doi: 10.1136/ard.2004.032813</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74(6):1011-1018. doi: 10.1136/annrheumdis-2013-204838</mixed-citation><mixed-citation xml:lang="en">Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74(6):1011-1018. doi: 10.1136/annrheumdis-2013-204838</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr. 2009; 22(10):1100-1108; quiz 1195. doi: 10.1016/j.echo.2009.06.023</mixed-citation><mixed-citation xml:lang="en">Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr. 2009; 22(10):1100-1108; quiz 1195. doi: 10.1016/j.echo.2009.06.023</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Endara SA, Dávalos GA, Fierro CH, et al. Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report. J Cardiothorac Surg. 2020;15(1):275. doi: 10.1186/s13019-020-01330-9</mixed-citation><mixed-citation xml:lang="en">Endara SA, Dávalos GA, Fierro CH, et al. Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report. J Cardiothorac Surg. 2020;15(1):275. doi: 10.1186/s13019-020-01330-9</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Takeuchi K, Izumi T, Nanaura H, et al. Mitral valve replacement for enlarged Libman-Sacks endocarditis in a patient with persistent primary antiphospholipid syndrome and recurrent stroke: a case report. Am J Case Rep. 2023;24:e938930. doi: 10.12659/AJCR.938930</mixed-citation><mixed-citation xml:lang="en">Takeuchi K, Izumi T, Nanaura H, et al. Mitral valve replacement for enlarged Libman-Sacks endocarditis in a patient with persistent primary antiphospholipid syndrome and recurrent stroke: a case report. Am J Case Rep. 2023;24:e938930. doi: 10.12659/AJCR.938930</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Roldan CA, Qualls CR, Sopko KS, et al. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol. 2008;35(2):224-229. PMID: 18085739</mixed-citation><mixed-citation xml:lang="en">Roldan CA, Qualls CR, Sopko KS, et al. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol. 2008;35(2):224-229. PMID: 18085739</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Shroff H, Benenstein R, Freedberg R, et al. Mitral valve Libman-Sacks endocarditis visualized by real time three-dimensional transesophageal echocardiography. Echocardiography. 2012;29(4):E100-1. doi: 10.1111/j.1540-8175.2011.01602.x</mixed-citation><mixed-citation xml:lang="en">Shroff H, Benenstein R, Freedberg R, et al. Mitral valve Libman-Sacks endocarditis visualized by real time three-dimensional transesophageal echocardiography. Echocardiography. 2012;29(4):E100-1. doi: 10.1111/j.1540-8175.2011.01602.x</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Capecchi M, Abbattista M, Ciavarella A, et al. Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med. 2022;11(23):6984. doi: 10.3390/jcm11236984</mixed-citation><mixed-citation xml:lang="en">Capecchi M, Abbattista M, Ciavarella A, et al. Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med. 2022;11(23):6984. doi: 10.3390/jcm11236984</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-12. doi: 10.1002/art.33340</mixed-citation><mixed-citation xml:lang="en">Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-12. doi: 10.1002/art.33340</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013;52(8):1397-1403. doi: 10.1093/rheumatology/kes388</mixed-citation><mixed-citation xml:lang="en">Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013;52(8):1397-1403. doi: 10.1093/rheumatology/kes388</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12(7):518-523. doi: 10.1191/0961203303lu391oa</mixed-citation><mixed-citation xml:lang="en">Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12(7):518-523. doi: 10.1191/0961203303lu391oa</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Yuriditsky E, Torres J, Izmirly PM, et al. Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review. Lupus. 2018;27(14):2269-2273. doi: 10.1177/0961203318804876</mixed-citation><mixed-citation xml:lang="en">Yuriditsky E, Torres J, Izmirly PM, et al. Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review. Lupus. 2018;27(14):2269-2273. doi: 10.1177/0961203318804876</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Arora S, Nair S, Prabhu R, et al. Role of direct oral anticoagulation agents as thromboprophylaxis in antiphospholipid syndrome. Cureus. 2021;13(10):e19009. doi: 10.7759/cureus.19009</mixed-citation><mixed-citation xml:lang="en">Arora S, Nair S, Prabhu R, et al. Role of direct oral anticoagulation agents as thromboprophylaxis in antiphospholipid syndrome. Cureus. 2021;13(10):e19009. doi: 10.7759/cureus.19009</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Skyrme-Jones RA, Wardrop CA, Wiles CM, et al. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1995;8(3):251-256. doi: 10.1016/s0894-7317(05)80034-3</mixed-citation><mixed-citation xml:lang="en">Skyrme-Jones RA, Wardrop CA, Wiles CM, et al. Transesophageal echocardiographic demonstration of resolution of mitral vegetations after warfarin in a patient with the primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1995;8(3):251-256. doi: 10.1016/s0894-7317(05)80034-3</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">O’Neill D, Magaldi J, Dobkins D, et al. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome. Arch Intern Med. 1995;155(3):325-327. PMID: 7832605</mixed-citation><mixed-citation xml:lang="en">O’Neill D, Magaldi J, Dobkins D, et al. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome. Arch Intern Med. 1995;155(3):325-327. PMID: 7832605</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Agirbasli MA, Hansen DE, Byrd BF 3rd. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1997; 10(8):877-880. doi: 10.1016/s0894-7317(97)70050-6</mixed-citation><mixed-citation xml:lang="en">Agirbasli MA, Hansen DE, Byrd BF 3rd. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr. 1997; 10(8):877-880. doi: 10.1016/s0894-7317(97)70050-6</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Ebato M, Kitai H, Kumakura H, et al. Thrombus on the tricuspid valve in a patient with primary antiphospholipid syndrome after implantation of an inferior vena cave filter. Circ J. 2002; 66(4):425-427. doi: 10.1253/circj.66.425</mixed-citation><mixed-citation xml:lang="en">Ebato M, Kitai H, Kumakura H, et al. Thrombus on the tricuspid valve in a patient with primary antiphospholipid syndrome after implantation of an inferior vena cave filter. Circ J. 2002; 66(4):425-427. doi: 10.1253/circj.66.425</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Tomcsányi J, Zsoldos A, Szabó M. Mitral and tricuspid valve thrombus in antiphospholipid syndrome. Heart. 2004;90(6):620. doi: 10.1136/hrt.2003.017434</mixed-citation><mixed-citation xml:lang="en">Tomcsányi J, Zsoldos A, Szabó M. Mitral and tricuspid valve thrombus in antiphospholipid syndrome. Heart. 2004;90(6):620. doi: 10.1136/hrt.2003.017434</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Brito FA, Tofani ML, Tofani FA, et al. Limban–Sacks endocarditis and oral anticoagulation. Arg Bras Cardiol 2004;82: 381–383. doi:10.1590/S0066-782X2004000400009</mixed-citation><mixed-citation xml:lang="en">Brito FA, Tofani ML, Tofani FA, et al. Limban–Sacks endocarditis and oral anticoagulation. Arg Bras Cardiol 2004;82: 381–383. doi:10.1590/S0066-782X2004000400009</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Ruan Y, Bridges JS, Kumar K, et al. Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome. Clin Rheumatol. 2008;27(12):1577-1579. doi: 10.1007/s10067-008-0991-0</mixed-citation><mixed-citation xml:lang="en">Ruan Y, Bridges JS, Kumar K, et al. Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome. Clin Rheumatol. 2008;27(12):1577-1579. doi: 10.1007/s10067-008-0991-0</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Salzberg SP, Nemirovsky D, Goldman ME, et al. Aortic valve vegetation without endocarditis. Ann Thorac Surg. 2009; 88(1):267-269. doi: 10.1016/j.athoracsur.2008.10.006</mixed-citation><mixed-citation xml:lang="en">Salzberg SP, Nemirovsky D, Goldman ME, et al. Aortic valve vegetation without endocarditis. Ann Thorac Surg. 2009; 88(1):267-269. doi: 10.1016/j.athoracsur.2008.10.006</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Prashanth P, Mukhaini M. Mitral valve leaflet and free-floating left atrial thrombi with “rhupus” and antiphospholipid syndrome. Br J Cardiol 2011;18(5):241–242. doi: 10.5837/bjc.2011.007</mixed-citation><mixed-citation xml:lang="en">Prashanth P, Mukhaini M. Mitral valve leaflet and free-floating left atrial thrombi with “rhupus” and antiphospholipid syndrome. Br J Cardiol 2011;18(5):241–242. doi: 10.5837/bjc.2011.007</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Stevanović D, Mačkić D, Džambasović E, et al. Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report. Journal of Health Sciences. 2014;4(1), 63–67. doi: 10.17532/jhsci.2014.149</mixed-citation><mixed-citation xml:lang="en">Stevanović D, Mačkić D, Džambasović E, et al. Antiphospholipid syndrome associated with non-infective mitral valve endocarditis: a case report. Journal of Health Sciences. 2014;4(1), 63–67. doi: 10.17532/jhsci.2014.149</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Rachwan RJ, Daher GE, Fares J, et al. Complete resolution of a large bicuspid aortic valve thrombus with anticoagulation in primary antiphospholipid syndrome. Front Cardiovasc Med. 2017;4:59. doi: 10.3389/fcvm.2017.00059</mixed-citation><mixed-citation xml:lang="en">Rachwan RJ, Daher GE, Fares J, et al. Complete resolution of a large bicuspid aortic valve thrombus with anticoagulation in primary antiphospholipid syndrome. Front Cardiovasc Med. 2017;4:59. doi: 10.3389/fcvm.2017.00059</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Sirinvaravong N, Rodriguez Ziccardi MC, Patnaik S, et al. Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. Oxf Med Case Reports. 2018;2018(6):omy024. doi: 10.1093/omcr/omy024</mixed-citation><mixed-citation xml:lang="en">Sirinvaravong N, Rodriguez Ziccardi MC, Patnaik S, et al. Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. Oxf Med Case Reports. 2018;2018(6):omy024. doi: 10.1093/omcr/omy024</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Granowicz E, Chung K. Improvement of cardiac vegetations in antiphospholipid syndrome with enoxaparin and corticosteroids after rivaroxaban failure. Case Rep Hematol. 2018;2018:8097539. doi: 10.1155/2018/8097539</mixed-citation><mixed-citation xml:lang="en">Granowicz E, Chung K. Improvement of cardiac vegetations in antiphospholipid syndrome with enoxaparin and corticosteroids after rivaroxaban failure. Case Rep Hematol. 2018;2018:8097539. doi: 10.1155/2018/8097539</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Kitano T, Sengoku K, Itotagawa E, et al. Dynamic morphological changes in Libman-Sacks endocarditis under different anticoagulation regimens. BMJ Case Rep. 2019;12(4):e229909. doi: 10.1136/bcr-2019-229909</mixed-citation><mixed-citation xml:lang="en">Kitano T, Sengoku K, Itotagawa E, et al. Dynamic morphological changes in Libman-Sacks endocarditis under different anticoagulation regimens. BMJ Case Rep. 2019;12(4):e229909. doi: 10.1136/bcr-2019-229909</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Shipman J, Agasthi P, Majdalany D, et al. Near complete resolution of nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome. Anatol J Cardiol. 2020;24(2):E5-E7. doi: 10.14744/AnatolJCardiol.2020.33027</mixed-citation><mixed-citation xml:lang="en">Shipman J, Agasthi P, Majdalany D, et al. Near complete resolution of nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome. Anatol J Cardiol. 2020;24(2):E5-E7. doi: 10.14744/AnatolJCardiol.2020.33027</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Haertel F, Kretzschmar D, Schulze PC, et al. Immunomodulation in antiphospholipid-antibody-associated endocarditis: a case report and review of the literature. Eur Heart J Case Rep. 2021; 5(12):ytab445. doi: 10.1093/ehjcr/ytab445</mixed-citation><mixed-citation xml:lang="en">Haertel F, Kretzschmar D, Schulze PC, et al. Immunomodulation in antiphospholipid-antibody-associated endocarditis: a case report and review of the literature. Eur Heart J Case Rep. 2021; 5(12):ytab445. doi: 10.1093/ehjcr/ytab445</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Bahar AR, Mishra T, Bahar Y, et al. Aortic valve vegetation due to nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome. CASE (Phila). 2024; 8(7):386-389. doi: 10.1016/j.case.2024.05.002</mixed-citation><mixed-citation xml:lang="en">Bahar AR, Mishra T, Bahar Y, et al. Aortic valve vegetation due to nonbacterial thrombotic endocarditis in a patient with antiphospholipid antibody syndrome. CASE (Phila). 2024; 8(7):386-389. doi: 10.1016/j.case.2024.05.002</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Bowden A, Walsh R, Murphy R, et al. A case of Libman-Sacks endocarditis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Eur Heart J Case Rep. 2024;8(10):ytae503. doi: 10.1093/ehjcr/ytae503</mixed-citation><mixed-citation xml:lang="en">Bowden A, Walsh R, Murphy R, et al. A case of Libman-Sacks endocarditis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Eur Heart J Case Rep. 2024;8(10):ytae503. doi: 10.1093/ehjcr/ytae503</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Mahajan K, Negi P, Merwaha R, et al. Isolated tricuspid valve Libman-Sacks endocarditis in a patient with antiphospholipid antibody syndrome. BMJ Case Rep. 2017; 2017:bcr2017219217. doi: 10.1136/bcr-2017-219217</mixed-citation><mixed-citation xml:lang="en">Mahajan K, Negi P, Merwaha R, et al. Isolated tricuspid valve Libman-Sacks endocarditis in a patient with antiphospholipid antibody syndrome. BMJ Case Rep. 2017; 2017:bcr2017219217. doi: 10.1136/bcr-2017-219217</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Bai Z, Hou J, Ren W, et al. Diagnosis and surgical treatment for isolated tricuspid Libman-Sacks endocarditis: a rare case report and literatures review. J Cardiothorac Surg. 2015;10:93. doi: 10.1186/s13019-015-0302-1.</mixed-citation><mixed-citation xml:lang="en">Bai Z, Hou J, Ren W, et al. Diagnosis and surgical treatment for isolated tricuspid Libman-Sacks endocarditis: a rare case report and literatures review. J Cardiothorac Surg. 2015;10:93. doi: 10.1186/s13019-015-0302-1.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Hubben A, McCrae KR. Emerging therapies in antiphospholipid syndrome. Transfus Med Rev. 2022;36(4):195-203. doi: 10.1016/j.tmrv.2022.09.002</mixed-citation><mixed-citation xml:lang="en">Hubben A, McCrae KR. Emerging therapies in antiphospholipid syndrome. Transfus Med Rev. 2022;36(4):195-203. doi: 10.1016/j.tmrv.2022.09.002</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome. Int J Mol Sci. 2023;24(2):1331. doi: 10.3390/ijms24021331</mixed-citation><mixed-citation xml:lang="en">Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome. Int J Mol Sci. 2023;24(2):1331. doi: 10.3390/ijms24021331</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Ginanjar E, Yulianto Y. Autoimmune disease with cardiac valves involvement: Libman-Sacks endocarditis. Acta Med Indones. 2017;49(2):148-150</mixed-citation><mixed-citation xml:lang="en">Ginanjar E, Yulianto Y. Autoimmune disease with cardiac valves involvement: Libman-Sacks endocarditis. Acta Med Indones. 2017;49(2):148-150</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Micallef S, Mallia Azzopardi C. Antiphospholipid syndrome masquerading as a case of infective endocarditis. BMJ Case Rep. 2018;2018:bcr2018224404. doi: 10.1136/bcr-2018-224404</mixed-citation><mixed-citation xml:lang="en">Micallef S, Mallia Azzopardi C. Antiphospholipid syndrome masquerading as a case of infective endocarditis. BMJ Case Rep. 2018;2018:bcr2018224404. doi: 10.1136/bcr-2018-224404</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Eviatar T, Niznik S, Elkayam O, Ben-Gal Y, Shavit R, Raanani E, Agmon-Levin N, Paran D. Heart valve surgery in antiphospholipid syndrome patients-morbidity and mortality. Life (Basel). 2023;13(4):891. doi: 10.3390/life13040891</mixed-citation><mixed-citation xml:lang="en">Eviatar T, Niznik S, Elkayam O, Ben-Gal Y, Shavit R, Raanani E, Agmon-Levin N, Paran D. Heart valve surgery in antiphospholipid syndrome patients-morbidity and mortality. Life (Basel). 2023;13(4):891. doi: 10.3390/life13040891</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Roldan CA, Sibbitt WL Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, Hayek RA, Charlton GA, Crookston K. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013;6(9):973-983. doi: 10.1016/j.jcmg.2013.04.012</mixed-citation><mixed-citation xml:lang="en">Roldan CA, Sibbitt WL Jr, Qualls CR, Jung RE, Greene ER, Gasparovic CM, Hayek RA, Charlton GA, Crookston K. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013;6(9):973-983. doi: 10.1016/j.jcmg.2013.04.012</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Colli A, Mestres CA, Espinosa G, Plasín MA, Pomar JL, Font J, Cervera R. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37(1):154-158. doi: 10.1016/j.ejcts.2009.06.046</mixed-citation><mixed-citation xml:lang="en">Colli A, Mestres CA, Espinosa G, Plasín MA, Pomar JL, Font J, Cervera R. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37(1):154-158. doi: 10.1016/j.ejcts.2009.06.046</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Hegde VA, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, Gradman A. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome — a case-series. Heart Lung Circ. 2007;16(6):423-7. doi: 10.1016/j.hlc.2007.03.010</mixed-citation><mixed-citation xml:lang="en">Hegde VA, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, Gradman A. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome — a case-series. Heart Lung Circ. 2007;16(6):423-7. doi: 10.1016/j.hlc.2007.03.010</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Erdozain JG, Ruiz-Irastorza G, Segura MI, Amigo MC, Espinosa G, Pomar JL, Perez-Valero I, Ateka-Barrutia O, Khamashta MA. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64(8):1256-1260. doi: 10.1002/acr.21670</mixed-citation><mixed-citation xml:lang="en">Erdozain JG, Ruiz-Irastorza G, Segura MI, Amigo MC, Espinosa G, Pomar JL, Perez-Valero I, Ateka-Barrutia O, Khamashta MA. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64(8):1256-1260. doi: 10.1002/acr.21670</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Chalvon NB, Costedoat-Chalumeau N, Pennaforte JL, et al. Severe Libman-Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases. Rheumatology (Oxford). 2023;62(2):707-715. doi: 10.1093/rheumatology/keac315</mixed-citation><mixed-citation xml:lang="en">Chalvon NB, Costedoat-Chalumeau N, Pennaforte JL, et al. Severe Libman-Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases. Rheumatology (Oxford). 2023;62(2):707-715. doi: 10.1093/rheumatology/keac315</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Masoumi S, Parizad R, Parvizi R, et al. Recurrence of valvular involvement in Libman-Sacks endocarditis associated with antiphospholipid syndrome: A case report. Clin Case Rep. 2024; 12(9): e9352. doi: 10.1002/ccr3.9352</mixed-citation><mixed-citation xml:lang="en">Masoumi S, Parizad R, Parvizi R, et al. Recurrence of valvular involvement in Libman-Sacks endocarditis associated with antiphospholipid syndrome: A case report. Clin Case Rep. 2024; 12(9): e9352. doi: 10.1002/ccr3.9352</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33(2):168-81. doi: 10.1016/j.ejcts.2007.11.004</mixed-citation><mixed-citation xml:lang="en">Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33(2):168-81. doi: 10.1016/j.ejcts.2007.11.004</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414-420. doi: 10.1016/j.jtcvs.2003.07.016</mixed-citation><mixed-citation xml:lang="en">Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414-420. doi: 10.1016/j.jtcvs.2003.07.016</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
